Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma

Fig. 2

Effect of NAP1L1 expression on the prognoses of patients with different TNM stages. Kaplan–Meier analysis for OS displayed as the NAP1L1 low group versus the NAP1L1 high group in TNM stage I–II (a) and stage III–IV (b). Kaplan–Meier analysis for OS displayed as the NAP1L1 low group versus the NAP1L1 high group in TNM stage I–II (c) and stage III–IV (d) based on TCGA database. OS overall survival, TCGA The Cancer Genome Atlas

Back to article page